{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-059613","form_type":"8-K","ticker":"KYTX","cik":"0001994702","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.382743+00:00","generated_at":"2026-06-02T01:24:30.165948+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Kyverna Q1 net loss $26.7M; cash $369.8M; treated 30 patients cumulatively","bullets":["Net loss of $26.7M ($1.12 per share) vs net loss of $11.1M ($12.10 per share) in Q1 2023.","Cash, cash equivalents and marketable securities $369.8M as of March 31, 2024, including $336.2M net IPO proceeds.","Treated 30 patients cumulatively with KYV-101: 8 myasthenia gravis, 7 lupus nephritis, 4 multiple sclerosis.","KYV-101 granted FDA Orphan Drug Designation for myasthenia gravis; upcoming data at EULAR, ECTRIMS, ACR.","Net cash used in operations $25.5M in Q1 2024 vs $11.5M in Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-059613","json":"https://secwatch.observer/filing/0000950170-24-059613.json","markdown":"https://secwatch.observer/filing/0000950170-24-059613.md","text":"https://secwatch.observer/filing/0000950170-24-059613.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000095017024059613/0000950170-24-059613-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000095017024059613/kytx-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:24:30.165948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ed4c28eb2fd05f63c440f4bfc17062e852e3ddaa","claim":"Kyverna Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income a net loss of $26.7 million, EPS a net loss per common share of $1.12.","evidence_excerpt":"For the quarter ended March 31, 2024, the company reported a net loss of $26.7 million, or a net loss per common share of $1.12","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1994702/000095017024059613/0000950170-24-059613-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"a net loss of $26.7 million"},{"label":"EPS","value":"a net loss per common share of $1.12"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}